Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of recombinant human thrombopoietin for secondary prevention of chemotherapy-induced thrombocytopenia
ChiCTR2000033659Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Third People's Hospital
- Start
- Jun 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) and Non-hematologic malignancy (3 arms), sponsored by Zhengzhou Third People's Hospital. Primary endpoints: Platelet change range and Rate of patients whose platelets return to normal without delaying next chemotherapy cycle. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2000033659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033659.